Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 487-491

  Furuya, Kazuhiro ^a   Kaku, Ying ^a   Yoshida, Ken ^a   Joh, Kensuke ^b   Kurosaka, Daitaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sendai Shakaihoken Hospital   (Japan)

Author keywords

Angiogenesis; Collagen induced arthritis; Platelet derived growth factor; Sunitinib; Synovitis; Vascular endothelial growth factor

Indexed keywords

'CAYMAN'; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTIRHEUMATIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTHRITIS SCORE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; JOINT DESTRUCTION; MOUSE; NONHUMAN; OVARY CANCER; PATHOLOGICAL SCORE; PRIORITY JOURNAL; RECTUM CANCER; SCORING SYSTEM; SYNOVIUM; ANIMAL; ANKLE; ARTHRITIS, EXPERIMENTAL; DRUG EFFECTS; PATHOLOGY; TREATMENT OUTCOME; WRIST;

ANIMALS; ANKLE JOINT; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; BONE DENSITY; INDOLES; MICE; PYRROLES; TREATMENT OUTCOME; WRIST JOINT;

EID: 84900400345     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844295     Document Type: Article

References (20)

1. Peacock DJ. Banquerigo ML. Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J. Exp Med. 1992; 175: 1135-8
2. Oliver S J Banquerigo M L Brahn E. Suppression of collageninduced arthritis using an angiogenesis inhibitor AGM-1470 and a microtubule stabilizer taxol. Cell Immunol. 1994; 157: 291-9
3. de Bandt M. Grossin M. Weber AJ. Chopin M. Elbim C. Pla M. et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum. 2000; 43: 2056-63
4. Kurosaka D. Yoshida K. Yasuda J. Yasuda C. Noda K. Furuya K et al. The eff ect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. Scand J Rheumatol. 2007; 36: 434-41
5. Kurosaka D. Yoshida K. Yasuda J. Yokoyama T. Kingetsu I Yamaguchi N. et al. Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann Rheum Dis. 2003; 62: 677-9
6. Koch A E Harlow L A Haines G K Amento E P Unemori E N Wong WL et al. Vascular endothelial growth factor. Acytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 1994; 152: 4149-56
7. Lee SS. Joo YS. Kim WU. Min DJ. Min JK. Park SH. et al. Vascular endothelial growth factor levels in the serum and synovial fl uid of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2001; 19: 321-4
8. Giatromanolaki A. Sivridis E. Athanassou N. Zois E. Thorpe P E Brekken RA et al. The angiogenic pathway ' vascular endothelial growth factor/fl k-1(KDR)-receptor ' in rheumatoid arthritis and osteoarthritis. J. Pathol. 2001; 194: 101-8
9. Kurosaka D. Hirai K. Nishioka M. Miyamoto Y. Yoshida K Noda K. et al. Clinical signifi cance of serum levels of vascular endothelial growth factor angiopoietin-1 and angiopoietin-2 in patients with rheumatoid arthritis. JRheumatol. 2010; 37: 1121-8
10. Manley PW. Martiny-Baron G. Schlaeppi JM. Wood JM. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs. 2002; 11: 1715-36
11. Weidner N. Semple J P Welch W R Folkman J. Tumor angiogenesis and metastasis -correlation in invasive breast carcinoma. NEngl J Med. 1991; 324: 1-8
12. Nagengast WB. Lub-de Hooge MN. Oosting SF. den Dunnen WF Warnders FJ. Brouwers AH. et al. VEGF-PET imaging is a noninvasive biomarker showing diff erential changes in the tumor during sunitinib treatment. Cancer Res. 2011; 71: 143-53
13. Christensen J G. Apreclinical review of sunitinib amultitargeted receptor tyrosine kinase inhibitor with anti-Angiogenic and antitumour activities. Ann Oncol. 2007; 18(Suppl 10): X3-10
14. Dehlin M. Andersson S. Erlandsson M. Brisslert M. Bokarewa M. Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol. 2011; 90: 811-817
15. Huang D. Ding Y. Li Y. Luo WM. Zhang ZF. Snider J. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010; 70: 1053-62
16. Roskoski R J r. Sunitinib: VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007; 356: 323-8
17. Ceponis A. Konttinen Y T Takagi M. X u J W Sorsa T. Matucci-Cerinic M. et al. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: Correlation with synovial mast cell hyperplasia and infl ammation. J. Rheumatol. 1998; 25: 2304-14
18. Terabe F. Kitano M. Kawai M. Kuwahara Y. Hirano T. Arimitsu J et al. Imatinib mesylate inhibited rat adjuvant arthritis and PDGFdependent growth of synovial fi broblast via interference with the Akt signaling pathway. Mod Rheumatol. 2009; 19: 522-9
19. Juurikivi A. Sandler C. Lindstedt K A Kovanen P T Juutilainen T Leskinen MJ. et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: Potential approach to the treatment of arthritis. Ann Rheum Dis. 2005; 64: 1126-31
20. Bischof RJ. Zafi ropoulos D. Hamilton JA. Campbell IK. Exacerbation of acute infl ammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: Evidence of macrophage infi ltration and local proliferation. Clin Exp Immunol. 2000; 119: 361-7